Highlighted Paper selected by Editor-in-Chief : Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis : A Pilot Study

DOI Web Site Web Site PubMed 被引用文献3件 参考文献27件
  • Tanaka Motoko
    Department of Nephrology, Akebono Clinic
  • Miyamura Shigeyuki
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Imafuku Tadashi
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Tominaga Yuna
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Maeda Hitoshi
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Anraku Makoto
    Faculty of Pharmaceutical Sciences, Sojo University
  • Yamasaki Keishi
    Faculty of Pharmaceutical Sciences, Sojo University
  • Kadowaki Daisuke
    Faculty of Clinical Pharmaceutical Sciences, Kumamoto University
  • Ishima Yu
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Watanabe Hiroshi
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
  • Okuda Tomoko
    Department of Nephrology, Akebono Clinic
  • Itoh Kazuko
    Department of Nephrology, Akebono Clinic
  • Matsushita Kazutaka
    Department of Nephrology, Akebono Clinic
  • Fukagawa Masafumi
    Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine
  • Otagiri Masaki
    Faculty of Pharmaceutical Sciences, Sojo University
  • Maruyama Toru
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University

書誌事項

タイトル別名
  • Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study

この論文をさがす

抄録

A ferric citrate formulation for treating hyperphosphatemia is a new therapeutic that not only suppresses the accumulation of phosphorus in patients with chronic kidney disease-mineral bone disorders (CKD-MBD), but also ameliorates anemia caused by iron deficiency. In contrast, it has been demonstrated that intravenous iron injection markedly increases oxidative stress. This study was designed to investigate the effect of a ferric citrate formulation on oxidative stress in CKD-MBD patients receiving hemodialysis therapy. Fifteen CKD-MBD patients undergoing dialysis were enrolled in this study. The patients were orally administered a ferric citrate formulation for 6 months. Their plasma phosphorus concentrations remained unchanged with the switch from other phosphorus adsorbents to the ferric citrate formulation. In addition, the ferric citrate formulation generally allowed for dose reduction of an erythropoiesis stimulating agent with an increased hematopoietic effect. The average values of plasma ferritin level increased after the introduction of a ferric citrate formulation, but did not exceed 100 (ng/mL). Interestingly, oxidative stress markers did not increase significantly, and anti-oxidative capacity was not significantly decreased at 6 months after the drug administration. Similarly, no change was observed in any inflammation markers. The ferric citrate formulation induces negligible oxidative stress in CKD-MBD patients receiving dialysis under the present clinical condition.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (27)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ